Zacks Investment Research cut shares of MDxHealth SA (OTCMKTS:MXDHF) from a buy rating to a hold rating in a report issued on Saturday.
According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “
Shares of MDxHealth SA (OTCMKTS:MXDHF) opened at $4.31 on Friday. MDxHealth SA has a 52 week low of $4.26 and a 52 week high of $6.15.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MDxHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth SA and related companies with MarketBeat.com's FREE daily email newsletter.